RecruitingNot ApplicableNCT06904625

Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer

Sponsor

Institut Claudius Regaud

Enrollment

54 participants

Start Date

Aug 14, 2025

Study Type

INTERVENTIONAL

Conditions

Metastatic Breast Cancer Metastatic Prostate Cancer

Summary

This trial is a pilot, prospective, single-center study conducted in a population of patients with metastatic breast cancer (whatever the immunohistochemical subtype) or metastatic prostate cancer. The aim of this exploratory study is to compare the sensitivity of three different techniques (CellSearch®, Parsortix® and SmartCatch®) in detecting circulating tumor cells (CTCs). After the patient's agreement, and before starting anti-tumor treatment, a blood sample will be taken using the 3 different CTC detection techniques. Each patient will participate in the study for one day. A total of 54 evaluable patients (36 patients with metastatic breast cancer and 18 patients with metastatic prostate cancer) will be included in this interventional study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing different laboratory methods for capturing circulating tumor cells (cancer cells that break off from tumors and travel in the blood) in people with advanced breast or prostate cancer, to find the most reliable method for guiding treatment. **You may be eligible if...** - You have been diagnosed with metastatic breast cancer (any subtype) or prostate cancer - Your cancer has spread to multiple sites - You are about to start a new line of treatment (not yet started) - You are 18 or older with acceptable overall health (WHO performance status ≤2) - You are enrolled in the French social security system **You may NOT be eligible if...** - You have another serious condition that would interfere with the study - You have psychological, family, or social circumstances that would prevent study follow-up - You have already started a new treatment line for your cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTaking blood samples before starting treatment

For patient included in the metastatic breast cancer and prostate cancer, a blood sample will be taken (37 mL in total) for the CTCs detection using the 3 technologies (CellSearch®, Parsortix® and SmartCatch®). For 3 patients only, an additional blood volume (18 mL) will also be collected for tcDNA detection (exploratory analysis of 3 patients). For patient included in the metastatic breast cancer complementary cohort, a blood sample will be taken (56 mL in total) for the CTCs detection using Parsortix® and SmartCatch® technologies.

Locations(1)

IUCT-O

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06904625

Related Trials

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT0612028363 locations

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

NCT066782697 locations

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

NCT072527263 locations

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357108 locations

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

NCT0327531120 locations